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An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in
Advanced Non-small Cell Lung Cancer
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Patrick Peterson, PhD,** Astra M. Liepa, PharmD,** Patti Moore, MS,**
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Background: Patients with advanced non-small cell lung cancer
(NSCLC) require care that emphasizes symptom palliation in addi-
tion to extending survival. The low response rates and minimal
survival gains observed in second-line studies underscore the need
to assess treatment efficacy with symptomatic end points.
Methods: To characterize the relationship between patient-reported
health-related quality of life outcomes and efficacy end points
(tumor response, overall survival [OS], progression-free survival
[PFS]), retrospective analyses were performed on Lung Cancer
Symptom Scale (LCSS) data (n  488) from the phase III study of
pemetrexed (500 mg/m2 once every 3 weeks) versus docetaxel (75
mg/m2 once every 3 weeks) in advanced NSCLC. The LCSS data
consisted of patient ratings of six symptoms and three summary
items using 100-mm visual analogue scales. The mean maximum
improvement for each item was categorized according to best tumor
response, with statistical analyses based on a two-factor interaction
model (with treatment arm and response group as fixed factors).
Additional analyses pooled data between treatment arms and exam-
ined correlation (nonparametric and Pearson’s) of time to first
worsening of symptoms (TWS) with PFS and OS.
Results: All LCSS items, except hemoptysis, showed mean maxi-
mum improvement over baseline for responders and patients with
stable disease (p  0.01), with greater improvement associated with
response. Median TWS for each LCSS item ranged between 2.3
months (fatigue) and 7.0 months (cough), with correlation between
TWS and PFS and OS (all p values 0.017).
Conclusions: For most NSCLC patients, second-line chemotherapy
provides symptomatic improvement that is linked to standard effi-
cacy outcomes. Health-related quality of life data provides comple-
mentary efficacy information that can guide routine clinical practice.
Key Words: Pemetrexed, NSCLC, Docetaxel, Lung Cancer Symp-
tom Scale (LCSS), Time to worsening of symptoms (TWS).
(J Thorac Oncol. 2008;3: 30–36)
Second-line treatment of advanced non-small cell lungcancer (NSCLC) aims to extend survival while palliating
symptoms by reducing tumor burden or delaying tumor
progression. Traditional efficacy outcomes such as survival
and time to progression can be measured objectively, but data
regarding the impact of treatment on disease-related symp-
toms and health-related quality of life (HRQL) must be
obtained directly from the patient. Because patients with
advanced NSCLC experience significant burden from dis-
ease-related symptoms in terms of their physical, social, and
psychologic well-being, HRQL data have become increas-
ingly important for evaluating the benefit of treatment. Fur-
thermore, because second-line treatment of NSCLC is asso-
ciated with low response rates (10% with chemotherapy or
targeted therapies) and limited survival time,1,2 changes in
HRQL or symptom burden might be important additional end
points for describing the efficacy of palliative therapy.
A recent phase III study examined the efficacy of
pemetrexed versus docetaxel in patients with advanced
NSCLC previously treated with chemotherapy.3 The two
treatments had similar efficacy outcomes, including median
survival times (8.3 months for pemetrexed versus 7.9 months
for docetaxel), 1-year survival rates (29.7% for both arms),
median progression-free survival (PFS) times (2.9 months for
both arms), and tumor response rates (9.1% for pemetrexed
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versus 8.8% for docetaxel). The pemetrexed arm demon-
strated a favorable safety profile as measured by statistically
lower rates of grade 3/4 toxicity, and importantly, lower rates
of grade 3/4 neutropenia, febrile neutropenia, and neutropenia
with infection. Hospitalizations and associated supportive
care were also lower on the pemetrexed arm. Disease-related
symptoms and their impact were assessed with the Lung
Cancer Symptom Scale (LCSS), a reliable and validated
disease-specific instrument.4,5 Protocol-specified analyses re-
vealed comparable symptom palliation between arms as as-
sessed both by patients and by investigators.3 Further analysis
of the LCSS data examined the maximum improvement per
item and revealed that in both treatment groups, patients who
achieved an objective tumor response experienced the great-
est maximum improvement, but patients with stable disease
also experienced improvement.6
Although improvement in disease-related symptoms
and HRQL is clinically important, another potential benefit of
therapy is to delay the worsening of these outcomes. Two
recent publications examined the time to first worsening of
symptoms (TWS) in patients with advanced NSCLC. Bezjak
et al.7 reported the effectiveness of erlotinib in delaying the
first deterioration in cough, dyspnea, and pain in patients with
previously treated NSCLC. A retrospective analysis by Peter-
son et al.8 indicated a delay in TWS in patients with advanced
NSCLC receiving gemcitabine maintenance therapy immedi-
ately after first-line induction treatment with gemcitabine and
cisplatin; furthermore, the study suggested a moderate corre-
lation between delayed TWS and delayed disease progression
or death.
In this article, we present retrospective analyses of
prospectively collected patient-reported LCSS data from the
phase III study of pemetrexed versus docetaxel in patients with
advanced NSCLC previously treated with chemotherapy.3 The
primary objective was to better characterize the relationship
between patient-reported LCSS outcomes and standard effi-
cacy end points. Clarification of this relationship should help
both patients and physicians understand how the standard
efficacy outcomes are associated with patient-reported bene-
fits in disease-related symptoms and HRQL.
PATIENTS AND METHODS
Patients
The study on which these analyses were based3 in-
cluded the following key eligibility criteria: diagnosis of
stage III or IV NSCLC, only one prior chemotherapy regimen
for advanced disease, Eastern Cooperative Oncology Group
performance status of 0 to 2, adequate bone marrow, renal
and hepatic function, and written informed consent. Exclu-
sion criteria included prior docetaxel or pemetrexed therapy,
grade 3/4 peripheral neuropathy, weight loss 10% over the
previous 6 weeks, symptomatic brain metastases, uncon-
trolled pleural effusions, and the inability to interrupt aspirin
or other nonsteroidal anti-inflammatory agents for a 5- to
8-day period. This study was conducted in accordance with
the ethical principles stated in the Declaration of Helsinki or
the applicable guidelines on good clinical practice.
Study Design and Treatment
This was a large, phase III, multicenter, open-label,
randomized trial with the primary objective of overall sur-
vival (OS). Secondary objectives included comparisons of
PFS, tumor response rate, patient-reported outcomes using
the LCSS, and toxicity.
Patients received either pemetrexed (ALIMTA, Eli
Lilly and Company, Indianapolis, IN) 500 mg/m2 as a 10-
minute intravenous infusion or 75 mg/m2 docetaxel (Taxo-
tere, Sanofi-Aventis, France) as a 1-hour intravenous infusion
on day 1, every 21 days. Treatment was discontinued for
disease progression or intolerable toxicity, or on patient or
investigator request.
Patients on the pemetrexed arm were administered folic
acid, vitamin B12, and dexamethasone while on study. Pa-
tients received comprehensive baseline assessments and mon-
itoring at regular intervals. Toxicity evaluations were based
on the National Cancer Institute Common Toxicity Criteria,
version 2.0. Tumor measurements were assessed using South-
west Oncology Group criteria after every other cycle.9 (See
Hanna et al.3 for additional details regarding study design.)
Patient-Reported Outcomes Instrument
The LCSS is a validated instrument designed to assess
the impact of treatment on disease-related symptoms and
HRQL.4,5 The patient portion of the LCSS scale consists of
six symptom-specific questions that address cough, dyspnea,
fatigue, pain, hemoptysis, and anorexia, plus three summary
items on symptom distress, interference with activity level,
and global HRQL. The degree of impairment is recorded on
a 100-mm visual analogue scale, with scores reported from 0
to 100 and 0 representing the best score. The patient LCSS
instrument was self-administered before randomization,
weekly following the start of treatment, at treatment discon-
tinuation, and at the initial follow-up visits if the patient had
not initiated subsequent therapy. Only patients for whom
there were validated translations completed the LCSS.
As a complement to the patient LCSS, investigators
completed the observer LCSS, a clinician-rated instrument
that assesses the same six symptoms using a five-point scale.
Investigators completed the observer LCSS before random-
ization, at the end of each treatment cycle, at treatment
discontinuation, and at the initial follow-up visits if the
patient had not initiated subsequent therapy.
Statistical Analyses
The analyses reported in this publication focus exclu-
sively on patient-reported LCSS data. They include all ran-
domized patients, but necessarily excluded any patient miss-
ing the baseline LCSS assessment or missing all postbaseline
LCSS assessments. The first analysis considered maximum
improvement in patient-reported scores as previously re-
ported by de Marinis et al.6 For each of the nine LCSS items,
for each individual patient, maximum improvement was de-
fined as the largest reduction in on-study scores from the
baseline score. The mean maximum improvement for each
item was categorized according to best tumor response. A
two-factor interaction model (with treatment arm and re-
sponse group as fixed factors), using restricted maximum
Journal of Thoracic Oncology • Volume 3, Number 1, January 2008 NSCLC: Efficacy and LCSS Outcomes Relationship
Copyright © 2007 by the International Association for the Study of Lung Cancer 31
likelihood, was constructed and used for these statistical
evaluations. Subsequent summaries pooled results by treat-
ment arm.
The second analysis was the TWS. TWS was defined
for each patient and each LCSS item as the time from the date
of the first dose of study treatment to the first date of a 15-mm
increase or worsening in score over baseline (meaningful
change). If a 15-mm worsening did not occur, TWS was
censored at the last LCSS assessment. Meaningful change for
the patient LCSS has previously been reported as a 10- to
25-mm change, based on association with changes in other
clinical measures.5,10 The 15-mm definition of meaningful
change in individual LCSS items is also consistent with a
distributional definition, with 15 mm approximately equal to
one half the standard deviation of baseline scores.11,12
Although patients completed weekly LCSS assess-
ments, all TWS analyses reported in this manuscript are
based on the last LCSS assessment per 3-week cycle. Other
research has shown that assessments every 3 or 4 weeks are
sufficiently frequent.13 This also corresponds to the frequency
of physician assessments in routine clinical practice. Further-
more, results for previously reported TWS assessments were
based on a once every 3-week8 or once every 4-week cycle7;
thus, this choice facilitates comparison across studies. Anal-
yses of TWS results presented were pooled across pem-
etrexed and docetaxel treatment arms because initial by-
treatment analyses of TWS yielded no statistical or even
strong numerical differences between arms. Likewise, base-
line LCSS scores were similar (Table 1), previous LCSS
analyses had yielded no differences, compliance rates were
similar, and efficacy outcomes were similar between arms.3
For each of the nine LCSS items, the Kaplan-Meier method
was used to estimate parameters for TWS.14 Statistical de-
pendence (correlation) between TWS and PFS and between
TWS and OS was assessed using the Kendall’s Tau nonpara-
metric statistic.15 The correlation was further examined using
Pearson’s correlation and least-squares regression of natural
log-transformed TWS and PFS.
RESULTS
Patient Characteristics and Baseline LCSS Scores
The retrospective analyses presented here used pro-
spectively collected data from a study enrolling between
March 2001 and February 2002 in which 571 patients with
prior treatment for advanced NSCLC were randomly as-
signed to either pemetrexed or docetaxel. As detailed in an
earlier publication,3 baseline characteristics were well bal-
anced between treatment arms with 75% of patients in each
arm having stage IV disease and approximately 88% an
Eastern Cooperative Oncology Group performance status of 0
or 1. A validated translation of the LCSS survey was avail-
able for 554 (97.0%) of the 571 patients. Of these 554
patients, 488 (88.1%) completed at least a portion of the
baseline and one postbaseline LCSS survey and were in-
cluded in these analyses; compliance was balanced between
arms (85% for on-study assessments). Patient characteris-
tics for this LCSS subgroup and the two treatment arms that
comprise it were consistent with the overall study population.
Baseline LCSS scores were similar between treatment
arms as shown in Table 1. The median and range of scores
indicates that most patients had the potential both for im-
provement and worsening in most items. The low incidence
of patient-reported hemoptysis limited the opportunity for
improvement in hemoptysis, but was consistent with previous
studies.16,17 The standard deviation range (26.4–29.8) for all
symptoms except hemoptysis is consistent with the prespeci-
fied 15-mm definition for meaningful change based on the
statistical distribution of scores, such as one half the standard
deviation.11,12
LCSS Scores: Maximum Improvement from
Baseline
The two-factor analysis of maximum improvement
from baseline showed no significant differences between
treatment arms for any of the nine LCSS items; likewise,
there was no strong numerical difference between arms. This
result was consistent with all other efficacy and LCSS anal-
yses of this trial.3
When data for both treatment arms were pooled, all
LCSS items except hemoptysis showed statistically signifi-
cant mean maximum improvements from baseline for com-
plete or partial responders and patients with stable disease
(p  0.01). As illustrated in Figure 1, the magnitude of
improvement was greater for complete or partial responders,
but patients with stable disease also had significant improve-
ment. In contrast, patients with progressive disease reported
only worsening mean scores for each item.
Time to First Worsening of Symptoms
In the analysis of TWS, the median number of analyzed
postbaseline assessments was 4 (equal to the median number
of cycles of treatment), and 25% of the analysis population
had 7 or more postbaseline assessments. As with the maxi-
mum improvement from baseline results, the initial TWS
analysis by treatment yielded no statistical or even strong
numerical differences between arms, thus supporting the
decision to pool the data. Figure 2 shows the Kaplan-Meier
TABLE 1. Baseline LCSS Scoresa
Pemetrexed Baseline
Score (n  237)
Docetaxel Baseline
Score (n  251)
Mean  SD
Median
(range) Mean  SD
Median
(range)
Anorexia 30.4  28.3 24 (0–100) 30.7  28.9 23 (0–100)
Fatigue 37.7  26.4 38 (0–99) 38.8  29.3 42 (0–100)
Cough 29.4  26.9 24 (0–100) 30.5  27.6 24 (0–100)
Dyspnea 33.3  28.4 28 (0–100) 36.0  29.0 32 (0–100)
Hemoptysis 5.3  14.5 0 (0–91) 3.6  10.6 0 (0–100)
Pain 27.3  27.7 20 (0–100) 24.7  27.4 13 (0–100)
Symptom distress 32.6  28.5 28 (0–100) 31.4  29.4 24 (0–100)
Activity level 40.6  28.2 41 (0–100) 41.5  29.8 42 (0–100)
Global quality
of life
38.9  26.9 41 (0–100) 41.2  28.2 42 (0–100)
a Scores range 0 to 100, with lower scores representing lower symptom burden or
less interference with HRQL.
LCSS, Lung Cancer Symptom Scale; SD, standard deviation.
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graphs for each of the six symptom-specific LCSS items, and
Figure 3 displays the Kaplan-Meier graphs for the three
LCSS summary items using pooled treatment arm data. As
summarized in Table 2, the median time to worsening of
pulmonary symptoms, dyspnea and cough, was 2.8 and 7.0
months, respectively. The median time to worsening of anorexia
and fatigue was less than 3 months, and the median time to
worsening of pain was 3.6 months. The median time to wors-
ening for hemoptysis could not be estimated because so few (56)
patients reported a 15-mm worsening of that symptom.
For each LCSS item except hemoptysis, there was a
statistically significant nonparametric correlation between
TWS and both PFS and OS time (Table 2). Figure 4 illus-
trates the scatter plots and least squares linear regression of
the natural log-transformed PFS by TWS for each of the six
symptom-specific LCSS items. Pearson’s correlation coeffi-
cients between TWS and PFS ranged from 0.35 (fatigue) to
0.42 (cough). Of 368 patients with both a 15-mm worsening
of at least one of the six symptoms and observed progressive
disease or death, 73% had worsening of at least one symptom
within 1 month of the first dose, and 60% of this group of 368
had a PFS time 3 months. For patients who did not have
worsening of any symptom in the first month of treatment,
50% did not have observed disease progression or death; for
those who did have observed progressive disease or death,
43% had a PFS time 4 months.
FIGURE 1. Maximum improvement from
baseline LCSS items. The mean maximum im-
provement from baseline is shown for each
item, with data from both treatment arms
pooled, and categorized by best overall tumor
response group (complete or partial response,
stable disease, progressive disease). Four pa-
tients of the 488 did not have tumor response
data available. CR/PR, complete response/par-
tial response; PD, progressive disease; SD, sta-
ble disease; HRQL, health-related quality of life.
FIGURE 2. Kaplan-Meier TWS for LCSS symptom items. Kaplan-Meier graphs using pooled treatment arm data are shown for
each of the six symptom-specific LCSS items. The number of 15-mm worsening events is shown on the graph for each item,
along with the median and its 95% confidence interval.
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DISCUSSION
The analyses presented here further examined the dis-
ease-related symptom and HRQL data from a phase III study
that compared the efficacy and toxicity of pemetrexed versus
docetaxel in patients with advanced NSCLC previously
treated with chemotherapy.3 The efficacy results (survival,
response rate, and PFS) of the two agents were comparable,
and pemetrexed had significantly fewer side effects and a
more favorable safety profile. The similar efficacy outcomes
led to the approval of pemetrexed as second-line therapy in
advanced NSCLC in the United States and European Union.
Previously reported analyses of the LCSS showed no differ-
FIGURE 3. Kaplan-Meier TWS for LCSS sum-
mary items. Kaplan-Meier graphs using pooled
treatment arm data are shown for each of the
three LCSS summary items. The number of
15-mm worsening events is shown on the
graph for each item, along with the median
and its 95% confidence interval.
TABLE 2. Time to Worsening of Symptoms and Correlation with PFS and OS
LCSS Item (na) Worsening Eventsb
TWS in Months,
Median (95% CI)
Kendall
p Valuec for PFS
Kendall
p Valuec for OS
Anorexia (483) 228 2.8 (2.1, 4.2) 0.001 0.001
Fatigue (483) 233 2.3 (2.1, 3.2) 0.013 0.017
Cough (484) 186 7.0 (3.7, .) 0.001 0.001
Dyspnea (484) 221 2.8 (2.2, 4.4) 0.001 0.001
Hemoptysis (484) 56 Not Estimable 0.082 0.051
Pain (487) 209 3.6 (2.8, 5.1) 0.001 0.001
Symptoms distress (480) 212 3.5 (2.5, 4.5) 0.001 0.001
Activity level (485) 239 2.3 (2.1, 3.3) 0.001 0.004
Global quality of life (482) 213 3.3 (2.2, 5.6) 0.001 0.002
a Of the 488 patients who completed at least a portion of the baseline and one postbaseline LCSS survey, n is the number of patients who provided postbaseline LCSS data for
each specific LCSS item.
b The number of worsening events is the number of patients who reported a 15-mm increase or worsening of each specific symptom. For patients who did not report a 15-mm
worsening, TWS was censored at the last LCSS assessment.
c The Kendall statistic is a nonparametric measure of correlation (the smaller the p value, the stronger the correlation) for the indicated TWS variable with either PFS or OS.
PFS, progression-free survival; OS, overall survival; LCSS, Lung Cancer Symptom Scale; TWS, time to first worsening of symptoms; CI, confidence interval.
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ence in symptom palliation or HRQL between the treatment
arms.3 Although the lesser toxicity experienced by patients on
the pemetrexed arm is a valuable outcome, this relative
benefit was not reflected in the global HRQL score likely
because of influence of other factors, including tumor shrink-
age and symptom palliation seen in both treatment arms.
Because the two treatment arms had comparable efficacy
results and similar baseline LCSS scores, data from the two
arms were pooled for the additional HRQL and symptom
analyses reported here.
The current analyses demonstrated that patients with
advanced NSCLC who responded positively to chemother-
apy, as assessed radiologically, also reported symptom im-
provements (Figure 1). Patients with better responses (partial
or complete tumor responses) displayed a greater improve-
ment in symptoms than those with a best response of stable
disease. Yet, even patients with stable disease reported sta-
tistically significant maximum improvements. This result
shows that tumor stabilization can be considered a relevant
outcome of second-line treatment because of its correlation to
symptom palliation. Further analyses of TWS showed that
delayed worsening of disease-related symptoms was associ-
ated with delayed progressive disease and death. This obser-
vation may be helpful in a clinical setting as physicians are
often confronted with patients who have minor progression
and stable symptoms during treatment. These results suggest
that symptom assessments of the patient should be considered
and perhaps given more weight than minor radiologic
changes in guiding treatment decisions and evaluating the
effectiveness of therapy. The feasibility of collecting patient-
reported data is evident in this trial, given that almost all
patients were able to participate because of availability of
translations and nearly 90% provided sufficient data to be
included in the analyses.
In a recent report examining a parameter similar to
TWS, Bezjak et al.7 analyzed the “time to deterioration” of
patient-reported symptoms in the BR.21 trial, a randomized
phase III study that compared erlotinib versus placebo in
pretreated, advanced NSCLC.7 Bezjak et al. reported the
median time to deterioration for three of the patient-reported
symptoms and, in each case, found a longer time to deterio-
ration for the treated group over the placebo. The magnitude
of the benefit associated with pemetrexed and docetaxel in
terms of TWS differed from erlotinib depending on the
symptom being assessed. Relative to erlotinib in the BR.21
study, the median times to symptom worsening were longer
for cough and pain for pemetrexed and docetaxel (7.0 versus
4.9 months and 3.6 versus 2.9 months, respectively), but
shorter for dyspnea (2.8 versus 4.7 months). However, dif-
ferences in methodology limit direct comparisons of these
trials. The BR.21 trial assessed symptoms using the European
Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ) C30 and the
supplementary QLQ-LC13 lung module,18 which were ad-
ministered at 4-week intervals rather than the 3-week inter-
vals used in the current analyses. Furthermore, symptoms in
the EORTC instrument are assessed with a four-item Likert
scale, unlike the more continuous 100-mm visual analogue
scale of the LCSS. Meaningful change for the EORTC instru-
ment was defined as a 10-point change of scores that were
standardized to a 100-point scale. This definition of meaningful
change was based on research on multi-item HRQL domains,19
and not necessarily on one- or two-item symptom scales. Fur-
thermore, standard deviations for baseline scores from
FIGURE 4. Least-squares regression line for PFS and TWS. Scatter plots are shown depicting the least-squares regression line
for PFS (y axis) and TWS (x axis) for each of the six LCSS symptom items. All plots use the natural logarithmic scale.
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BR.21 are not reported. The standard deviations reported
for the current analyses are consistent with previous re-
ports for the LCSS in similar populations,16 and are also
supportive of the one-half standard deviation rule.11,12
In our analyses, delayed worsening of symptoms is
associated with delayed progressive disease and death, with a
moderate correlation between TWS and either PFS or OS. If
these results are confirmed in prospective studies, then as-
sessing the time to the first worsening of any of the symptoms
may be especially useful as an early measure of efficacy in
phase III interim analyses or randomized phase II trials with
limited follow-up. Other studies have found a similar corre-
lation. For example, Bukowski et al.20 used two patient-
reported outcome tools to assess the impact of sorafenib on
renal cancer symptoms and HRQL in a phase III placebo-
controlled trial. Sorafenib treatment was found to prolong
PFS and OS, while simultaneously delaying time to health
state deterioration over placebo in patients with advanced
renal cancer. Likewise, in a separate study of advanced
NSCLC, gemcitabine maintenance therapy was found to
delay both time to progressive disease and TWS as compared
with best supportive care.8
To summarize, the majority of advanced NSCLC pa-
tients who had previously received therapy and were treated
with pemetrexed or docetaxel showed improvement over
baseline disease-related symptoms and HRQOL. These anal-
yses provide evidence that chemotherapy is palliative in
addition to extending survival and PFS in advanced NSCLC.
These analyses also provide evidence that LCSS outcomes
are closely linked with more traditional efficacy results, (i)
because patients with stable disease or a partial or complete
response showed improvement over baseline, and (ii) because
TWS is correlated with survival and PFS. Thus, the LCSS
(and potentially other validated instruments focusing on dis-
ease-related symptoms) can provide both complementary
efficacy data, which are useful in clinical research and prac-
tice, and valuable information on the palliative effects of
treatment for patients and their physicians.
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